Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

相似書籍

• BMET-26 PHASE 2 STUDY OF VB-111, AN ANTI-CANCER GENE THERAPY, AS MONOTHERAPY FOLLOWED BY COMBINATION OF VB-111 WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
  由: Brenner, Andrew, et al.
  出版: (2015)
• ATIM-03. BIOMARKER ANALYSIS SUPPORTS THE VB-111 DUAL MECHANISM OF ACTION
  由: Gruslova, Aleksandra, et al.
  出版: (2017)
• NT-07 PHASE 1-2 DOSE-ESCALATION STUDY OF VB-111, AN ANTI-ANGIOGENIC GENE THERAPY, AS MONOTHERAPY AND IN COMBINATION WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
  由: Brenner, Andrew, et al.
  出版: (2014)
• A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
  由: Cloughesy, Timothy F, et al.
  出版: (2020)
• NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE)
  由: Ellingson, Benjamin, et al.
  出版: (2020)